OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities
2019.Sep.16
Announcement of phase II clinical trial result for ovarian cancer on OBI and Mackay Memorial Hospital cooperated Adagloxad Simolenin, OBI-822
2019.Sep.06
Announcement on change of research and development officer
2019.Aug.31
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase I/II Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
2019.Aug.12
Board of Directors Approved the Change of Financial Officer and Acting Spokesperson
2019.Aug.03
IND Phase I/II Human Clinical Trial Application of Globo-H Antibody-Drug Conjugate, OBI-999, submission to FDA
2019.Jul.31
Announcement on Change of Financial Officer and Acting Spokesperson
2019.Jul.29
Subsidiary AP Biosciences and Tasly Biopharmaceuticals Signed Cooperative Development and Authorized Agreement of New Antibody Drug
